- Home
- PTC vs BIIB Comparison
PTC vs BIIB Comparison
Compare PTC & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTC
- BIIB
- Stock Information
- Founded
- PTC 1985
- BIIB 1978
- Country
- PTC United States
- BIIB United States
- Employees
- PTC N/A
- BIIB N/A
- Industry
- PTC Computer Software: Prepackaged Software
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- PTC Technology
- BIIB Health Care
- Exchange
- PTC Nasdaq
- BIIB Nasdaq
- Market Cap
- PTC 22.2B
- BIIB 20.6B
- IPO Year
- PTC 1989
- BIIB 1991
- Fundamental
- Price
- PTC $161.65
- BIIB $140.60
- Analyst Decision
- PTC Buy
- BIIB Buy
- Analyst Count
- PTC 11
- BIIB 27
- Target Price
- PTC $211.00
- BIIB $220.50
- AVG Volume (30 Days)
- PTC 1.4M
- BIIB 1.6M
- Earning Date
- PTC 02-05-2025
- BIIB 02-12-2025
- Dividend Yield
- PTC N/A
- BIIB N/A
- EPS Growth
- PTC 63.98
- BIIB 40.28
- EPS
- PTC 3.25
- BIIB 11.18
- Revenue
- PTC $2,313,386,000.00
- BIIB $9,675,900,000.00
- Revenue This Year
- PTC $9.33
- BIIB N/A
- Revenue Next Year
- PTC $10.27
- BIIB N/A
- P/E Ratio
- PTC $49.76
- BIIB $12.58
- Revenue Growth
- PTC 6.05
- BIIB N/A
- 52 Week Low
- PTC $161.02
- BIIB $128.51
- 52 Week High
- PTC $203.09
- BIIB $238.00
- Technical
- Relative Strength Index (RSI)
- PTC 24.54
- BIIB 44.88
- Support Level
- PTC $164.68
- BIIB $135.02
- Resistance Level
- PTC $172.09
- BIIB $141.69
- Average True Range (ATR)
- PTC 5.02
- BIIB 4.00
- MACD
- PTC -1.30
- BIIB 0.04
- Stochastic Oscillator
- PTC 1.94
- BIIB 59.44
About PTC PTC Inc.
PTC offers high-end computer-assisted design (Creo) and product lifecycle management (Windchill) software as well as Internet of Things and AR industrial solutions. Founded in 1985, PTC has 28,000 customers, with revenue stemming mostly from North America (45%) and Europe (40%).
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.